Developer docs
API playgroundTry for free, no card

Search company profiles

Endevica Bio

Full company profile

uuid0000uj1

Namestring
Endevica Bio
Legal namestring
Endevica Bio, Inc.
Websiteurl
endevicabio.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide therapeutics that target the melanocortin system (MC3R/MC4R receptors) to treat metabolic diseases. The company is headquartered in Northbrook, Illinois (incorporated in Delaware), was founded in 2009, and operates with a small, focused team of 11–50 chemists, biologists, and computational chemists. Its proprietary peptidomimetics platform designs peptides capable of crossing the blood-brain barrier to modulate central melanocortin receptors, exploiting the discovery that TCMCB07 is transported by a multi-specific bile salt carrier — a technically demanding capability that distinguishes the platform from conventional CNS-targeted approaches.

The company's pipeline comprises two clinical-stage drug candidates. TCMCB07 (mifomelatide) is a dual MC3R/MC4R antagonist peptide currently in a Phase 2 trial (NCT06937177) for preventing weight loss and cachexia in patients with stage 4 metastatic colorectal cancer undergoing chemotherapy; Phase 1 results showed positive safety and a 1.07 kg weight difference vs placebo (p=0.0195). 710GO is an oral dual MC3R/MC4R agonist for general obesity treatment, with Phase 1 in healthy overweight/obese volunteers planned for the first half of 2026, and preclinical primate data showing 11.7% body weight reduction with minimal lean mass loss and only 1.1% weight rebound seven weeks post-treatment. In March 2026, Endevica spun out Kalohexis to advance the obesity and metabolic disease portfolio, with Endevica's leadership team leading the new entity.

Endevica Bio is pre-revenue with no commercial products. Revenue is expected to materialize post-FDA approval through pharmaceutical partnerships or direct sales. To date the company has raised approximately $14 million cumulatively, including a $10 million Series B in January 2023, plus earlier non-dilutive funding from the National Cancer Institute and Centennial Investors. The go-to-market motion relies on conducting clinical trials in partnership with CROs (e.g., WuXi Clinical for the Phase 2 program) and eventually commercializing through pharma partnerships or direct sales channels targeting oncology practices (cachexia) and obesity-treating providers. The company maintains a content-driven marketing approach emphasizing peer-reviewed publication and disease awareness, targeting an addressable market projected to reach USD 4.1 billion by 2032 for the cancer cachexia segment alone.

Short descriptiontext

Endevica Bio is a clinical-stage biotechnology company developing first-in-class peptide therapeutics that target the melanocortin system to treat cancer cachexia (mifomelatide, Phase 2) and obesity (710GO, Phase 1 planned 2026). The company is pre-revenue and headquartered in Northbrook, Illinois.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNorthbrook, United States
HQ citystring
Northbrook
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, clinical-stage biopharmaceuticals, cancer cachexia treatment, metabolic disease drugs, melanocortin receptor modulators
Industry3 codes
PRIMARYHLAAAHAH
Ophthalmology Biosimilars
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage biopharmaceuticals / Peptide therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company. Revenue will be generated through commercialization of drug candidates upon regulatory approval, potentially through partnerships with pharmaceutical companies or direct sales.

endevicabio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide drug candidates that modulate the melanocortin system (MC3R/MC4R) for metabolic diseases. Its pipeline includes TCMCB07 (mifomelatide), a dual MC3R/MC4R antagonist peptide in Phase 2 development for preventing and treating cancer cachexia, and 710GO, an oral dual MC3R/MC4R agonist in preclinical development for general obesity treatment. Both candidates leverage a proprietary platform for designing peptides that cross the blood-brain barrier.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 11.7% body weight reduction over 15 weeks in obese nonhuman primates with 710GO monotherapy
+5 more records
Product overview1 text field

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide drug candidates that modulate the melanocortin system for metabolic diseases. The company's pipeline includes two clinical-stage drug candidates: TCMCB07 (mifomelatide), a dual MC3R/MC4R antagonist peptide in Phase 2 development for preventing and treating cancer cachexia; and 710GO, an oral dual MC3R/MC4R agonist in Phase 1 development for general obesity treatment. Both candidates leverage the melanocortin system's role in regulating metabolic homeostasis, appetite, and body weight.

Product and service2 records
1TCMCB07 (mifomelatide)
CategoryPeptide drug candidate - oncology supportive care
Description

A dual melanocortin-3 and -4 receptor (MC3R/MC4R) antagonist peptide drug candidate in clinical development for the treatment and prevention of cachexia in cancer patients undergoing chemotherapy. Designed to cross the blood-brain barrier and modulate the body's behavioral and metabolic response to chronic illness, preserving lean mass and fat mass.

2710GO
CategoryPeptide drug candidate - metabolic disease / obesity
Description

An oral dual MC3R/MC4R agonist peptide designed to activate the melanocortin system to induce weight loss for treatment of general obesity. Demonstrated preclinical efficacy in obese nonhuman primates with limited lean mass loss and minimal weight rebound after treatment cessation.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Kalohexis was spun out from Endevica Bio in March 2026 to advance the clinical development of melanocortin drug candidates for obesity and metabolic diseases. The Endevica Bio leadership team leads the newly spun-out company. Kalohexis is advancing 710GO for obesity and mifomelatide for cachexia.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

WuXi Clinical is serving as the clinical research partner for Endevica Bio's Phase 2 trial of TCMCB07. The partnership enables the trial to be conducted across 20 sites with 100 patients diagnosed with stage 4 metastatic colorectal cancer.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct melanocortin-system peer developing setmelanotide (an MC4R agonist) for rare genetic forms of obesity. Most directly comparable company given the shared MC-pathway mechanism and metabolic-disease focus.

TypeDirect peer
Description

Melanocortin-peptide specialist (bremelanotide for HSDD, MC1R/MC4R programs). Comparable peptide platform targeting melanocortin receptors and small team characteristic of clinical-stage biotechs.

TypeDirect peer
Description

Clinical-stage peptide therapeutics company focused on endocrine/metabolic diseases (paltusotine for acromegaly). Comparable peptide modality, similar clinical-stage profile, and overlapping therapeutic area in endocrinology and metabolism.

TypeDirect peer
Description

Peptide therapeutics company developing dasiglucagon, glepaglutide, and other peptide drugs for metabolic and rare diseases. Direct comparison on peptide platform technology and metabolic indication strategy.

TypeEmerging player
Description

Clinical-stage biotech developing therapies for metabolic diseases of aging, including obesity and related conditions. Comparable metabolic-disease focus with overlapping patient populations.

TypeBroad incumbent
Description

Broad incumbent in obesity via tirzepatide and retatrutide (GLP-1/GIP/glucagon agonists). Represents the dominant commercial competitor to melanocortin-based obesity therapies like 710GO, and a likely acquirer or partner candidate.

TypeBroad incumbent
Description

Global GLP-1 leader (semaglutide) in obesity and type 2 diabetes. The dominant incumbent whose franchise success defines the competitive context for any novel obesity mechanism including 710GO.

TypeDirect peer
Description

Clinical-stage company developing S-pindolol for cancer cachexia and other muscle-wasting conditions. Closest direct competitor in the cachexia indication that TCMCB07 targets.

TypeEmerging player
Description

Clinical-to-commercial biotech in metabolic liver disease (resmetirom for MASH). Comparable profile of a focused metabolic-disease company with first-in-class positioning and similar regulatory pathway dynamics.

TypeEmerging player
Description

Clinical-stage biotech developing diazoxide choline controlled-release for hyperphagia in Prader-Willi syndrome. Comparable small-cap, single-asset clinical-stage biotech focused on a rare metabolic disorder with high unmet need.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Endevica Bio

Clinical-stage biopharmaceuticals / Peptide therapeuticsendevicabio.com

Endevica Bio is a clinical-stage biotechnology company developing first-in-class peptide therapeutics that target the melanocortin system to treat cancer cachexia (mifomelatide, Phase 2) and obesity (710GO, Phase 1 planned 2026). The company is pre-revenue and headquartered in Northbrook, Illinois.

What Endevica Bio does

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide therapeutics that target the melanocortin system (MC3R/MC4R receptors) to treat metabolic diseases. The company is headquartered in Northbrook, Illinois (incorporated in Delaware), was founded in 2009, and operates with a small, focused team of 11–50 chemists, biologists, and computational chemists. Its proprietary peptidomimetics platform designs peptides capable of crossing the blood-brain barrier to modulate central melanocortin receptors, exploiting the discovery that TCMCB07 is transported by a multi-specific bile salt carrier — a technically demanding capability that distinguishes the platform from conventional CNS-targeted approaches.

The company's pipeline comprises two clinical-stage drug candidates. TCMCB07 (mifomelatide) is a dual MC3R/MC4R antagonist peptide currently in a Phase 2 trial (NCT06937177) for preventing weight loss and cachexia in patients with stage 4 metastatic colorectal cancer undergoing chemotherapy; Phase 1 results showed positive safety and a 1.07 kg weight difference vs placebo (p=0.0195). 710GO is an oral dual MC3R/MC4R agonist for general obesity treatment, with Phase 1 in healthy overweight/obese volunteers planned for the first half of 2026, and preclinical primate data showing 11.7% body weight reduction with minimal lean mass loss and only 1.1% weight rebound seven weeks post-treatment. In March 2026, Endevica spun out Kalohexis to advance the obesity and metabolic disease portfolio, with Endevica's leadership team leading the new entity.

Endevica Bio is pre-revenue with no commercial products. Revenue is expected to materialize post-FDA approval through pharmaceutical partnerships or direct sales. To date the company has raised approximately $14 million cumulatively, including a $10 million Series B in January 2023, plus earlier non-dilutive funding from the National Cancer Institute and Centennial Investors. The go-to-market motion relies on conducting clinical trials in partnership with CROs (e.g., WuXi Clinical for the Phase 2 program) and eventually commercializing through pharma partnerships or direct sales channels targeting oncology practices (cachexia) and obesity-treating providers. The company maintains a content-driven marketing approach emphasizing peer-reviewed publication and disease awareness, targeting an addressable market projected to reach USD 4.1 billion by 2032 for the cancer cachexia segment alone.

Endevica Bio firmographics

Firmographics
Name
Endevica Bio
Legal name
Endevica Bio, Inc.
Website
https://endevicabio.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Endevica Bio is a clinical-stage biotechnology company developing first-in-class peptide therapeutics that target the melanocortin system to treat cancer cachexia (mifomelatide, Phase 2) and obesity (710GO, Phase 1 planned 2026). The company is pre-revenue and headquartered in Northbrook, Illinois.
Ownership category
akta.pro rank

Endevica Bio industry classification

Industry
Product category
Clinical-stage biopharmaceuticals / Peptide therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAHAH
Ophthalmology Biosimilars
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Peptide therapeutics
  • Clinical-stage biopharmaceuticals
  • Cancer cachexia treatment
  • Metabolic disease drugs
  • Melanocortin receptor modulators

Where Endevica Bio is headquartered

Location

Headquarters

HQ city
Northbrook
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Endevica Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company. Revenue will be generated through commercialization of drug candidates upon regulatory approval, potentially through partnerships with pharmaceutical companies or direct sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Endevica Bio product offering

Product offering

Core offering

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide drug candidates that modulate the melanocortin system (MC3R/MC4R) for metabolic diseases. Its pipeline includes TCMCB07 (mifomelatide), a dual MC3R/MC4R antagonist peptide in Phase 2 development for preventing and treating cancer cachexia, and 710GO, an oral dual MC3R/MC4R agonist in preclinical development for general obesity treatment. Both candidates leverage a proprietary platform for designing peptides that cross the blood-brain barrier.

Product overview

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide drug candidates that modulate the melanocortin system for metabolic diseases. The company's pipeline includes two clinical-stage drug candidates: TCMCB07 (mifomelatide), a dual MC3R/MC4R antagonist peptide in Phase 2 development for preventing and treating cancer cachexia; and 710GO, an oral dual MC3R/MC4R agonist in Phase 1 development for general obesity treatment. Both candidates leverage the melanocortin system's role in regulating metabolic homeostasis, appetite, and body weight.

Differentiator

Problem solved

Functional benefit

Products and services

  • TCMCB07 (mifomelatide) A dual melanocortin-3 and -4 receptor (MC3R/MC4R) antagonist peptide drug candidate in clinical development for the treatment and prevention of cachexia in cancer patients undergoing chemotherapy. Designed to cross the blood-brain barrier and modulate the body's behavioral and metabolic response to chronic illness, preserving lean mass and fat mass.
  • 710GO An oral dual MC3R/MC4R agonist peptide designed to activate the melanocortin system to induce weight loss for treatment of general obesity. Demonstrated preclinical efficacy in obese nonhuman primates with limited lean mass loss and minimal weight rebound after treatment cessation.

Quantifiable outcome

  • 11.7% body weight reduction over 15 weeks in obese nonhuman primates with 710GO monotherapy
  • +5 more outcomes

Companies that use Endevica Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Endevica Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Endevica Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • KalohexiscoreStrategic or Co-development Partner · 1 March 2026Kalohexis was spun out from Endevica Bio in March 2026 to advance the clinical development of melanocortin drug candidates for obesity and metabolic diseases. The Endevica Bio leadership team leads the newly spun-out company. Kalohexis is advancing 710GO for obesity and mifomelatide for cachexia.
  • WuXi ClinicalcoreStrategic or Co-development Partner · 1 April 2025WuXi Clinical is serving as the clinical research partner for Endevica Bio's Phase 2 trial of TCMCB07. The partnership enables the trial to be conducted across 20 sites with 100 patients diagnosed with stage 4 metastatic colorectal cancer.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Endevica Bio competitors and assessment

Company assessment

Direct peers

  • Rhythm Pharmaceuticals: Direct melanocortin-system peer developing setmelanotide (an MC4R agonist) for rare genetic forms of obesity. Most directly comparable company given the shared MC-pathway mechanism and metabolic-disease focus.
  • Palatin Technologies: Melanocortin-peptide specialist (bremelanotide for HSDD, MC1R/MC4R programs). Comparable peptide platform targeting melanocortin receptors and small team characteristic of clinical-stage biotechs.
  • Crinetics Pharmaceuticals: Clinical-stage peptide therapeutics company focused on endocrine/metabolic diseases (paltusotine for acromegaly). Comparable peptide modality, similar clinical-stage profile, and overlapping therapeutic area in endocrinology and metabolism.
  • Zealand Pharma: Peptide therapeutics company developing dasiglucagon, glepaglutide, and other peptide drugs for metabolic and rare diseases. Direct comparison on peptide platform technology and metabolic indication strategy.
  • Actimed Therapeutics: Clinical-stage company developing S-pindolol for cancer cachexia and other muscle-wasting conditions. Closest direct competitor in the cachexia indication that TCMCB07 targets.

Emerging players

  • BioAge Labs: Clinical-stage biotech developing therapies for metabolic diseases of aging, including obesity and related conditions. Comparable metabolic-disease focus with overlapping patient populations.
  • Madrigal Pharmaceuticals: Clinical-to-commercial biotech in metabolic liver disease (resmetirom for MASH). Comparable profile of a focused metabolic-disease company with first-in-class positioning and similar regulatory pathway dynamics.
  • Soleno Therapeutics: Clinical-stage biotech developing diazoxide choline controlled-release for hyperphagia in Prader-Willi syndrome. Comparable small-cap, single-asset clinical-stage biotech focused on a rare metabolic disorder with high unmet need.

Broad incumbents

  • Eli Lilly: Broad incumbent in obesity via tirzepatide and retatrutide (GLP-1/GIP/glucagon agonists). Represents the dominant commercial competitor to melanocortin-based obesity therapies like 710GO, and a likely acquirer or partner candidate.
  • Novo Nordisk: Global GLP-1 leader (semaglutide) in obesity and type 2 diabetes. The dominant incumbent whose franchise success defines the competitive context for any novel obesity mechanism including 710GO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Endevica Bio social profiles

Digital presence

Endevica Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Endevica Bio leadership team

Management profile

Number of profiles

Profiles2 records

Endevica Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Endevica Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endevica Bio

What does Endevica Bio do?

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide drug candidates that modulate the melanocortin system (MC3R/MC4R) for metabolic diseases. Its pipeline includes TCMCB07 (mifomelatide), a dual MC3R/MC4R antagonist peptide in Phase 2 development for preventing and treating cancer cachexia, and 710GO, an oral dual MC3R/MC4R agonist in preclinical development for general obesity treatment. Both candidates leverage a proprietary platform for designing peptides that cross the blood-brain barrier.

Is Endevica Bio a public or private company?

Endevica Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Endevica Bio founded?

Endevica Bio was founded in 2009. It employs 11 to 50 people.

Where is Endevica Bio based?

Endevica Bio is headquartered in Northbrook, United States, in the North America region.

How does Endevica Bio make money?

One revenue line is on record: drug Development and Commercialization.

Who are Endevica Bio's main competitors?

Direct peers on record are Rhythm Pharmaceuticals, Palatin Technologies, Crinetics Pharmaceuticals, Zealand Pharma and Actimed Therapeutics. Emerging players are BioAge Labs, Madrigal Pharmaceuticals and Soleno Therapeutics. Broad incumbents are Eli Lilly and Novo Nordisk.

Does Endevica Bio have an API?

No public API is recorded for Endevica Bio.

What industry is Endevica Bio in?

Endevica Bio's product category is Clinical-stage biopharmaceuticals / Peptide therapeutics. Its primary akta.pro industry code is HLAAAHAH, Ophthalmology Biosimilars, with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Targeted OncologyTCMCB07 Enters Phase 2 for Weight Loss in Stage IV Colorectal CancerEndevica Bio has initiated a phase 2 clinical trial for TCMCB07, a melanocortin-3/4 antagonist peptide candidate, to prevent weight loss in patients with stage IV colorectal cancer undergoing chemotherapy. The study, conducted in partnership with WuXi Clinical, will enroll 100 patients across 20 sites and aims to address the unmet clinical need for treating cancer cachexia following promising phase 1 results.BioSpaceObesity newcomer Kalohexis makes confidential IPO bid 3 months after spinoffKalohexis, an obesity-focused drugmaker spun out from Endevica Bio in March, has submitted a confidential registration statement with the SEC for an initial public offering, keeping details including share count, proceeds, and timing under wraps. The company's most advanced asset is mifomelatide in Phase 2 for cancer cachexia, while EBMC-710GO targets early-stage obesity development through a non-GLP-1 mechanism targeting MC3R/MC4R receptors. The biotech IPO market has rebounded significantly, with over 15 companies filing to go public this year compared to eight in the prior year.YahooKalohexis confidentially files IPO to back obesity and cachexia portfolioMetabolic health-focused drug developer Kalohexis has confidentially filed for an IPO with the SEC, four months after spinning out from Endevica Bio in March 2026. The clinical-stage biotech is developing treatments for obesity and cancer cachexia through melanocortin system modulation, with lead programs mifomelatide in Phase II for cancer cachexia and 710GO in Phase I for obesity. The filing comes amid a wave of record-breaking biotech IPOs in 2026, including Kailera Therapeutics' $625m and Parabilis Medicines' $670m offerings.Pharmaceutical TechnologyKalohexis confidentially files IPO to back obesity and cachexia portfolio - Pharmaceutical TechnologyKalohexis, a metabolic health-focused drug developer spun out of Endevica Bio in March 2026, has confidentially filed a draft registration statement with the US Securities and Exchange Commission for an initial public offering. The clinical-stage biotech is advancing two melanocortin-based peptide therapeutics: mifomelatide in Phase II for cancer cachexia and 710GO in Phase I for obesity, with the obesity market alone projected to reach $173.5bn across seven major markets by 2031. The IPO filing comes amid a surge in US biotech IPOs in 2026, including record-breaking offerings from Kailera Therapeutics ($625m) and Parabilis Medicines ($670m).FierceBiotechEndevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1sKalohexis, a clinical-stage biotech that spun out from Endevica Bio in March, has confidentially submitted an IPO registration statement to the Securities and Exchange Commission to support its obesity and cancer cachexia treatment pipeline. The company is developing 710GO, an oral dual MC3R/MC4R agonist in phase 1 for weight loss, and mifomelatide, an injectable dual MC3R/MC4R antagonist in phase 2 for cancer cachexia. Kalohexis claims its melanocortin receptor-targeting approach offers advantages over GLP-1 drugs, including avoiding side effects such as lean body mass loss and gastrointestinal distress, positioning itself as a potential competitor in the obesity treatment market.BioSpaceKalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026Kalohexis presented data at ENDO 2026 showing its oral dual MC3R/MC4R agonist 710GO reduced caloric intake and induced weight loss in obese nonhuman primates. Over 15 weeks, chronic dosing achieved 11.8% weight loss versus vehicle, with limited rebound and preserved lean mass, and no cardiovascular changes at doses up to 60 mg/kg. The drug is in a Phase 1 clinical trial for general obesity.PancanPanCAN PurpleStride Chicago Premier Sponsor Endevica Bio: Founded on the Mission to Find a Cure for CachexiaEndevica Bio has joined the PanCAN PurpleStride Chicago event as a first-time Premier Sponsor to support pancreatic cancer research and patient advocacy. The company, led by Co-Founder Dan Marks, is developing novel therapies to treat cachexia, a debilitating weight loss condition affecting up to 80% of pancreatic cancer patients for which no effective drugs currently exist.GlobeNewswireCancer Cachexia Clinical Trial Pipeline Shows Potential with Active Contributions from 18+ Key Companies | DelveInsightDelveInsight's 'Cancer Cachexia Pipeline Insight 2025' report identifies 18+ companies actively developing 20+ pipeline drugs for cancer cachexia, a wasting syndrome affecting up to 87% of pancreatic and gastric cancer patients. Recent clinical milestones include Endevica Bio dosing the first patient in a Phase II trial for TCMCB07 (April 2025), CSPC Pharmaceutical Group receiving FDA approval for JMT203 (April 2025), GenFleet Therapeutics securing NMPA approval for GFS202A (March 2025), Tensegrity Pharma completing a ¥650 million seed funding round (January 2025), and Meta Fines receiving MFDS approval for ASCA101CC Phase II trial (January 2025).Clinical Trials ArenaEndeveco Bio spin-off to launch obesity trialEndevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate 710GO into clinical trials. The company aims to initiate a Phase I trial of the peptide in the second half of 2025, leveraging preclinical data showing significant weight loss in animal models. This move positions Endevica Bio to compete in the heavily dominated GLP-1 receptor agonist market alongside major players like Eli Lilly and Novo Nordisk.PR NewswireEndevica Bio Spins Off New Company to Develop Weight Loss DrugEndevica Bio announced the spin-off of a new company, Abisati, to develop 710GO, an oral MC4R agonist for weight loss. The drug has demonstrated efficacy in animal studies, and Abisati plans to initiate phase 1 trials in the second half of 2025. This strategic move allows Endevica Bio to continue its broader research while Abisati focuses exclusively on bringing the weight-loss treatment to market.